[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
University of California, Los Angeles · Emory University · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
120
total citations
- FWCI
- 44.48
- Percentile
- 100%
- References
- 32
Citations per year
Authors
22Topics & keywords
Topics
Keywords
- Open label
- Renal cell carcinoma
- Medicine
- Nuclear medicine
- Oncology
- Clinical trial
- Internal medicine
No related works found for this paper.
Funding
- UDU.S. Department of Justice
- BSBristol-Myers Squibb
- PPfizer
- SOSociety of Nuclear Medicine and Molecular Imaging
- ANAustralian Nuclear Science and Technology Organisation
- RPRegeneron Pharmaceuticals
- ISIntuitive Surgical
- APActinium Pharmaceuticals
- EExelixis
- NINational Imaging Facility
- PPProgenics Pharmaceuticals
- VLVerily Life Sciences
- VVeracyte
- YTY-mAbs Therapeutics
- ACAustralian Cancer Research Foundation
- NBNational Breast Cancer Foundation
- APAstellas Pharma
- IIpsen
- AAAustralian and New Zealand Society of Nuclear Medicine
- MRMedical Research Council
- NHNational Health and Medical Research Council